This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garland, L. L. Articles by Eder, J. P. Search for Related Content PubMed PubMed Citation Articles by Garland, L. L. Articles by Eder, J. P.

A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

Authors' Affiliations: ¹ Arizona Cancer Center, University of Arizona, Tucson, Arizona; ² Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; ³ Arizona Cancer Center, University of Arizona, Scottsdale, Arizona; ⁴ Massachusetts General Hospital, Harvard University; ⁵ Dana-Farber Cancer Center, Harvard University, Boston, Massachusetts; ⁶ M.D. Anderson Cancer Center, University of Texas, Houston, Texas; and ⁷ Pfizer Global Research and Development, Ann Arbor, Michigan

Requests for reprints: Linda L. Garland, Arizona Cancer Center, 1515 North Campbell Avenue, Ste. 1969E, Tucson, AZ 85724. Phone: 520-626-3434; Fax: 520-626-2225; E-mail: lgarland{at}azcc.arizona.edu.

Purpose: CI-1033 is an orally available 4-anilinoquinazolone irreversible tyrosine kinase inhibitor of erbB-1, erbB-2, and erbB-4. We conducted a dose escalation study of CI-1033 with docetaxel to assess the safety profile and pharmacokinetics of the combination and to establish the maximum tolerated dose.

Experimental Design: Twenty-six patients with advanced solid tumors were treated on four dosing cohorts starting at CI-1033 (50 mg/d) + docetaxel (75 mg/m²). An intermittent dosing schedule avoided concurrent drug dosing.

Results: CI-1033 alone was escalated from 50 to 75 mg/d (dose level 2), where diarrhea was dose limiting; a 38% incidence of cycle 1 febrile neutropenia prompted dose de-escalation of both CI-1033 and docetaxel for dose level 3, where dose-limiting toxicities prompted further de-escalation of CI-1033 to 45 mg/d. Given equivalent safety profiles for dose level 1 [CI-1033 (50 mg/d) + docetaxel (75 mg/m²)] and dose level 4 [CI-1033 (45 mg/d) + docetaxel (60 mg/m²)], the former was determined to be the recommended phase II dose, given greater dose intensity of both drugs. Antitumor activity was noted in three patients, including a complete response in a patient with cervix uteri cancer. Pharmacokinetic analysis showed a possible effect of docetaxel on CI-1033 pharmacokinetics.

Conclusions: It is feasible to combine the irreversible pan-erbB tyrosine kinase inhibitor CI-1033 with docetaxel on an intermittent dosing schedule in advanced cancer patients. We established the maximum tolerated dose and recommended phase II dose for the combination. Further investigation of this combination should include a rigorous analysis of the effect of docetaxel on CI-1033 pharmacokinetics.

This article has been cited by other articles:

				L. V. Sequist Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Oncologist, March 1, 2007; 12(3): 325 - 330. [Abstract] [Full Text] [PDF]